OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical & Translational Immunology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Endothelial cells are not productively infected by SARS‐CoV‐2	94
Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients	82
A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination	81
CAR‐NK cells: the next wave of cellular therapy for cancer	74
Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models	59
Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand	52
Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro	48
Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2	46
Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19	46
Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors	45
Rheumatoid arthritis CD14⁺ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease	43
Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody‐associated disease	41
Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019	39
Arrested development: suppression of NK cell function in the tumor microenvironment	39
The up‐to‐date pathophysiology of Kawasaki disease	38
Natural killer cells in inflammatory autoimmune diseases	37
Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection	37
The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: a potential therapeutic target for inflammatory disorders	35
Type 1 conventional dendritic cells and interferons are required for spontaneous CD4⁺ and CD8⁺ T‐cell protective responses to breast cancer	34
SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation	34
RGD‐binding integrins and TGF‐β in SARS‐CoV‐2 infections – novel targets to treat COVID‐19 patients?	34
Prophylactic antigen‐specific T‐cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant	31
Cardiovascular disease in SARS‐CoV‐2 infection	31
Cerebrospinal fluid metabolomics: detection of neuroinflammation in human central nervous system disease	31
TGF‐β‐secreting regulatory B cells: unsung players in immune regulation	29

Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics	29
Ligelizumab treatment for severe asthma: learnings from the clinical development programme	28
Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay	28